[Form 4] Natera, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Natera insider reported a minor disposition of common stock via charitable contribution. Solomon Moshkevich, listed as President, Clinical Diagnostics and an officer of Natera, executed a gift of 300 shares of Natera common stock on 09/15/2025, recorded as a disposition at $0 per share. After the reported transaction he beneficially owns 120,559 shares directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025 and notes the sale was a charitable contribution.

Insights

Financial Analyst

TL;DR: Officer donated a small block of shares; immaterial to company value but reduces insider holdings slightly.

The reported transaction is a non-market disposition of 300 shares executed as a charitable contribution, which does not generate proceeds for the seller and therefore does not reflect a liquidity-driven sale. The remaining direct beneficial ownership of 120,559 shares is stated, and the filing follows Section 16 reporting requirements. For investors, this transaction is routine and does not indicate a material change in insider alignment or company prospects given the small size relative to total outstanding shares.

Corporate Governance Expert

TL;DR: Compliance filing shows timely disclosure of an officer's charitable gift; governance procedures appear followed.

The Form 4 documents an insider disclosure consistent with disclosure rules: transaction date, nature (charitable contribution), post-transaction holdings, and an authorized signature by an attorney-in-fact. This indicates adherence to reporting obligations and does not raise governance red flags. The filing contains no indication of other related-party arrangements or accelerated vesting events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		G		300(1)	D	$0	120,559	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a charitable contribution by the Reporting Person.

	/s/ Vincent Fontanilla, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did NTRA insider Solomon Moshkevich report on Form 4?

The filing reports a disposition of 300 shares of Natera common stock on 09/15/2025 recorded as a charitable contribution.

How many NTRA shares does the reporting person own after the transaction?

The reporting person beneficially owns 120,559 shares directly following the reported transaction.

What was the reported price for the disposition on the Form 4?

The transaction is recorded at a price of $0, reflecting a charitable contribution rather than a market sale.

What is the reporting person's role at Natera (NTRA)?

The Form 4 identifies Solomon Moshkevich as an officer with the title President, Clinical Diagnostics.

When was the Form 4 signed and filed?

The signature by an attorney-in-fact is dated 09/17/2025; the earliest transaction date disclosed is 09/15/2025.